Biocon (532523) Stock Overview
Manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
532523 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Biocon Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹424.65 |
| 52 Week High | ₹440.30 |
| 52 Week Low | ₹331.00 |
| Beta | 0.32 |
| 1 Month Change | 3.06% |
| 3 Month Change | 24.84% |
| 1 Year Change | 14.14% |
| 3 Year Change | 66.92% |
| 5 Year Change | 9.63% |
| Change since IPO | 952.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532523 | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | 2.3% | 2.2% | 1.0% |
| 1Y | 14.1% | 13.5% | -1.4% |
Return vs Industry: 532523 matched the Indian Biotechs industry which returned 13.5% over the past year.
Return vs Market: 532523 exceeded the Indian Market which returned -1.4% over the past year.
Price Volatility
| 532523 volatility | |
|---|---|
| 532523 Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 532523 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532523's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 16,420 | Shreehas Tambe | www.biocon.com |
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept.
Biocon Limited Fundamentals Summary
| 532523 fundamental statistics | |
|---|---|
| Market cap | ₹686.67b |
| Earnings (TTM) | ₹3.86b |
| Revenue (TTM) | ₹169.27b |
Is 532523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532523 income statement (TTM) | |
|---|---|
| Revenue | ₹169.27b |
| Cost of Revenue | ₹56.91b |
| Gross Profit | ₹112.36b |
| Other Expenses | ₹108.51b |
| Earnings | ₹3.86b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.38 |
| Gross Margin | 66.38% |
| Net Profit Margin | 2.28% |
| Debt/Equity Ratio | 40.5% |
How did 532523 perform over the long term?
See historical performance and comparisonDividends
Does 532523 pay a reliable dividends?
See 532523 dividend history and benchmarks| Biocon dividend dates | |
|---|---|
| Ex Dividend Date | Jul 03 2026 |
| Dividend Pay Date | Aug 31 2026 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 55 days |
Does 532523 pay a reliable dividends?
See 532523 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 19:50 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biocon Limited is covered by 39 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |